|
||
|
Nemunaitis J, Khuri FR, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. Journal of Clinical Oncology, 19(2): 289-298, 2001. Pisters KW, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS. Phase I trial of oral green tea extract in adult patients with solid tumors. Journal of Clinical Oncology, 19(6): 1830-1838, 2001. Shin DM, Donato NJ, Cooper M, Perez-Soler R, Shin HJ, Wu, JY, Zhang P, Lawhorn, K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. Epidermal growth factor receptor-targeted therapy with humanized chimeric monoclonal antibody, C225 in combination with cisplatin in patients with head and neck cancer. Clinical Cancer Research, 7(5): 1204-1213, 2001. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers J, Morrison W, Gillenwater A, Ang K-K, Lippman SM, Goepfert H, Hong WK. Combined interferon- a , 13-cis-retinoic acid, and a -tocopherol in locally advanced head and neck squamous cell carcinoma: Novel bioadjuvant phase II trial. Journal of Clinical Oncology, 19;(12): 3010-3017, 2001. Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang K-K, Goepfert H, Lippman SM, Hong WK. Phase II study of paclitaxel, ifosfamide, Carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer, 91 (7): 1316-1323, 2001. Khuri FR , Kim ES, Lee JJ, Winn RJ, Benner SE, Spitz MR, Lippman SM, Fu KK, Cooper JS, Vokes ER, Chamberlain RM, Stetz J, Williams B, Pajak TF, Goepfert H, Hong WK. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiological Biomarkers Prevention, 10(8): 823-829, 2001. Moore RJ, Doherty DA; Do KA, Chamberlain RM, Khuri FR. Racial disparity in survival of patients with squamous cell carcinoma of the oral cavity and pharynx. Ethnicity and Health, 6(3): 165-177, 2001. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JM, El-Naggar AK, Roach J, Ginsberg L, Thall PF, Wang X, Teddy S, Lawhorn K, Zentgraf R, Steinhaus G, Abbruzzesse J, Hong WK, Herbst R. Phase II study of the anti-angiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer, 92(9): 2364-2737, 2001. Ang K, Weber R, Vokes E, Trotti A, Chapman D, Cooper J, Forastiere A, Fu KK, Hammond E, Khuri FR, Leveque FS, Leupold N, Eisbruch A, Mack C, Mukherji S, Paja TF, Ridge JA. Radiation therapy oncology group: Research Plan 2002-2006, Head and Neck Cancer Committee. International Journal of Radiation Oncology and Biological Physics, 51(3) Suppl 2, 39-43, 2001. Hong, J-I., Smith, T.J., Ho, C-T., August, D.A., and Yang, C.S. Effect of purified green and black tea polyphenols on cyclooxygenase and lipoxygenase-dependent metabolism of arachidonic acid in the human colon mucosa and colon tumor tissues. Biochem. Pharmcol., 62: 1175-1183, 2001. Nomura, M., Kaji, A., He, Z., Ma, W-Y., Miyamoto, K-i., Yang, C.S., Dong, Z. Inhibitory Mechanisms of Tea Polyphenols on the Ultraviolet B-activated Phosphatidylinositol 3-Kinase-dependent Pathway. J. Biol. Chem., 276: 46624-46631, 2001. Li, C., Meng, X., Winnik, B., Lee, M-J., Lu, H., Sheng, S., Buckley, B., and Yang, C.S. Analysis of urinary metabolites of tea catechins by liquid chromatography/electrospray ionization mass spectrometry. Chem. Res. Toxicol.,14: 702-707, 2001. Lu, Y-P., Lou, Y-R., Lin, Y., Shih, W.J., Huang, M-T., Yang, C.S., and Conney, A.H. Inhibitory effects of orally administered green tea, black tea and caffeine on skin carcinogenesis in mice previously treated with ultraviolet B light (high risk mice): Relationship to decreased tissue fat. Cancer Res., 61: 5002-5009, 2001. Chung, J.Y., Park, J.O., Phyu, H.P., Dong, Z., Yang, C.S. Mechanisms of inhibition of the ras-MAP kinase signaling pathway in 30.7b ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3'-digallate. FASEB J., 15: 2022-2024, 2001. Meng, X., Lee, M-L., Li, C., Sheng, S., Zhu, N., Sang, S., Ho, C-T., and Yang, C.S. Formation and identification of 4'-O-methyl-(-)-epigallocatechin in humans. Drug Metab. Dispos.,29:789-793, 2001. Yang, C.S., Landau, J.M., Huang, M-T., and Newmark, H.L. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr., (invited review) 21:381-406, 2001. |
|
Chow, H-H.S., Cai, Y., Alberts, D.S., Hakim, I., Dorr, R., Shahi, F., Crowell, A., Viner, J., and Yang, C.S. Phase I pharmacokinetic study of tea polyphenols following single dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol. Biomark. Prev., 10:53-58, 2001. Schinazi, R.F, Hurwitz, S.J., Liberman, I., Juodawlkis, A., Shi, J., Liotta, D.C., Coderre, J., & Olson, J., 2001. Preclinical development of b -5-o-carboranyl-2'-deoxyuridine (D-CDU) for the treatment of malignant brain tumors. Frontiers in Neutron Capture Therapy edited by Hawthorne et al., Plenum Publishers, New York, pp 1121-1124. Guan B, Yue P, Clayman GL, Sun S-Y. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol, 188: 98-105, 2001. Sun S-Y, Yue P, Kelloff GJ, Steele VE, Lippman SM, Hong WK, Lotan R. Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide (4HPR) in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. Cancer Epidemiology, Biomarkers & Prevention, 10: 595-101, 2001. Sun S-Y, Yue P, Zhou J-Y, Wang Y, Choi H-R, Lotan R, Wu GS. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun, 280: 788-797, 2001. Chen AY , Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, Goepfert H. The development and validation of a dysphagia-specific questionnaire for head and neck cancer patients: the M.D. Anderson Dysphagia Inventory (MDADI). Arch Otolaryngol Head Neck Surg 2001 July;127(7):870-6. Chen AY , Matson L, Roberts D, Goepfert H. The significance of comorbidity in advanced laryngeal carcinoma. Head Neck 2001 July;23(7):566-72. Chen AY , Levy L, Goepfert H, Brown B, Spitz M, Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer 2001;92:225-31. Chen AY, Myers JN. Cancer of the oral cavity. Disease-A-Month 2001;47(7):275-361. Chen, J., Fujii, K., Zhang, L., Roberts, T., and Fu, H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci U S A, 98: 7783-7788, 2001 . Subramanian, R. R., Masters, S. C., Zhang, H., and Fu, H. Functional conservation of 14-3-3 isoforms in inhibiting bad-induced apoptosis. Exp Cell Res, 271: 142-151, 2001. Masters, S. C., Yang, H., Datta, S. R., Greenberg, M. E., and Fu, H. 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Mol Pharmacol, 60: 1325-1331, 2001.
Masters, S. C. and Fu, H. 14-3-3 proteins mediate an essential anti-apoptotic signal. J Biol Chem, 276: 45193-45200, 2001. Snyder, J. P., Nettles, J. H., Cornett, B., Downing, K. H., and Nogales, E. The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A, 98: 5312-5316, 2001.
Venkatesan, H., Davis, M. C., Altas, Y., Snyder, J. P., and Liotta, D. C. Total synthesis of SR 121463 A, a highly potent and selective vasopressin v(2) receptor antagonist. J Org Chem, 66: 3653-3661, 2001. Barboni, L., Lambertucci, C., Appendino, G., Vander Velde, D. G., Himes, R. H., Bombardelli, E., Wang, M., and Snyder, J. P. Synthesis and NMR-driven conformational analysis of taxol analogues conformationally constrained on the C13 side chain. J Med Chem, 44: 1576-1587, 2001. Barboni, L., Datta, A., Dutta, D., Georg, G. I., Vander Velde, D. G., Himes, R. H., Wang, M., and
Snyder, J. P. Novel d-seco paclitaxel analogues: synthesis, biological evaluation, and model testing. J Org Chem, 66: 3321-3329, 2001. Khuri, F. R., Lee, J. S., Lippman, S. M., Lee, J. J., Kalapurakal, S., Yu, R., Ro, J. Y., Morice, R. C., Hong, W. K., and Hittelman, W. N. Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers. Cancer Epidemiol Biomarkers Prev, 10: 311-318, 2001. Giannakakou, P., Robey, R., Fojo, T., and Blagosklonny, M. V. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene, 20: 3806-3813, 2001. Nicolaou, K. C., Namoto, K., Ritzen, A., Ulven, T., Shoji, M., Li, J., D'Amico, G., Liotta, D., French, C. T., Wartmann, M., Altmann, K. H., and Giannakakou, P. Chemical synthesis and biological evaluation of cis- and trans-12,13-cyclopropyl and 12,13-cyclobutyl epothilones and related pyridine side chain analogues. J Am Chem Soc, 123: 9313-9323, 2001. Nicolaou, K. C., Namoto, K., Li, J., Ritzen, A., Ulven, T., Shoji, M., Zaharevitz, D., Gussio, R., Sackett, D. L., Ward, R. D., Hensler, A., Fojo, T., and
Giannakakou, P. Synthesis and biological evaluation of 12,13-cyclopropyl and 12,13-cyclobutyl epothilones. Chembiochem, 2: 69-75, 2001. Shin, D. M., Charuruks, N., Lippman, S. M., Lee, J. J., Ro, J. Y., Hong, W. K., and Hittelman, W. N. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev, 10: 603-609, 2001.
Kim, J., Shin, D. M., El-Naggar, A., Lee, J. S., Corrales, C., Lippman, S. M., Hong, W. K., and Hittelman, W. N. Chromosome polysomy and histological characteristics in oral premalignant lesions. Cancer Epidemiol Biomarkers Prev, 10: 319-325, 2001. Dillard, D. G., Muller, S., Cohen, C., Bloch, D., Del Gaudio, J. M., and Gal, A. A. High tumor grade in salivary gland mucoepidermoid carcinomas and loss of expression of transforming growth factor beta receptor type II. Arch Otolaryngol Head Neck Surg, 127: 683-686, 2001.
|
||
|
||
| Last update: July 31st, 2008 by Robert Fu & Edwin Shin |
||